Jasper Therapeutics (JSPR)

The company’s lead drug candidate is briquilimab, a monoclonal antibody designed to interfere with stem cell factor signaling through the CD117, or KIT, receptor. KIT is expressed on mast cells and certain stem cells, and signaling through this pathway is important for mast cell survival and activation. By blocking stem cell factor from binding to CD117, briquilimab is intended to reduce the number or activity of disease-driving mast cells and address inflammation at an upstream point in the disease process.

Jasper’s strategy is to test briquilimab in conditions where existing treatments may not provide adequate control for all patients, particularly those with persistent symptoms despite standard therapies. As a biotechnology company without a broad commercial product portfolio, its business is centered on research and development, clinical trial execution, regulatory progress, and the ability to demonstrate safety and efficacy in defined patient populations.

Jasper Therapeutics is listed as JSPR and operates in a high-risk, high-potential segment of the healthcare market. Its value proposition is tied closely to the clinical development of briquilimab and the broader scientific case for targeting mast cells through the SCF-KIT pathway.